QNCX
Quince Therapeutics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
cortexyme is developing therapeutics based on data supporting a new theory of the cause of alzheimer's and other degenerative disorders. cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration and beta amyloid production. the target has been validated in a number of animal models and cortexyme is currently moving a proprietary small molecule towards human clinical testing.
Market Cap: 50.2 Million
Primary Exchange: NASDAQ
Website: cortexyme.com
Shares Outstanding: 42.9 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.6905191328984449
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Ethical Flags
Longest drawdown: 248 trading days
From: 2023-04-04 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|